by Amy Berger | Jul 7, 2021 | News, Publications and Press
IITRI is proud to share the promising news from multiple sponsors of COVID-19 in vitro and in vivo studies. Links below to press releases and recent publications. Congrats all! New IITRI Co-Author Publication: Scalable live-attenuated SARS-CoV-2 vaccine...
by Amy Berger | Apr 22, 2021 | Blog, News
IITRI now has access to multiple SARS-CoV-2 variants. Currently available: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma). Available soon: B.1.617.1 (Kappa) and B.1.617.2 (Delta) These variants are available for use in our assays (immunostain and neutralization) as well...
by Amy Berger | Mar 24, 2021 | Blog
Spread the Word: IITRI has 40+ Years of Experience in GLP Inhalation Studies Many inhalation professionals are unaware that IITRI provides complete end-to-end inhalation toxicology study programs for IND and NDA submissions. We have decades of expertise in aerosol...
by Amy Berger | Jan 27, 2021 | Blog, News
IITRI now offers an improved efficacy assay for looking at effects of drugs on SARS-CoV-2. Although this assay no longer includes a cytotoxicity readout, we offer a neutral red assay in BSl-2 instead if needed. This current assay uses immunostaining and provides more...
by Amy Berger | Nov 24, 2020 | Uncategorized
IITRI now offers three different animals depending on the specifications and needs of your study. Transgenic mouse model: – K18-hACE2 transgenic mouse model – Clinical signs such as body weight loss, mortality – Viral load in nasal washes Ferret model: –...
Recent Comments